Study study type PathologyT1T0Patientssample sizesROB Results deaths (OS) Eprogression or deaths (PFS) ERFS/DFS E

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus letrozole
lapatinib plus letrozole
EGF30008 (all population), 2009
  NCT00073528
RCTla/mBC - HR-positive - 1st line (L1)lapatinib plus letrozoleplacebo plus letrozolePostmenopausal women with histologically confirmed stage IIIB/IIIC or IV, with HR positive. No prior therapy for advanced/metastatic BC was allowed, bu prior (neo)adjuvant antiestrogen therapy was allowed.642 / 644NA
conclusif demonstrated-14%
EGF30008 (HER2-positive), 2009
  NCT00073528
RCTla/mBC - HR-positive - 1st line (L1)lapatinib plus letrozoleplacebo plus letrozolePostmenopausal women with histologically confirmed stage IIIB/IIIC or IV, with HR positive. No prior therapy for advanced/metastatic BC was allowed, bu prior (neo)adjuvant antiestrogen therapy was allowed.111 / 108NA
conclusif -26% demonstrated-29%